Novo Nordisk Expands Obesity Treatment Access in Japan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NVO?
Source: seekingalpha
- Self-Funded Treatment Pathways: Novo Nordisk aims to broaden access to GLP-1 drug Wegovy by collaborating with physicians and patients on self-funded treatment options, addressing the issue that many individuals cannot access treatment for various reasons.
- Intensifying Market Competition: The company is experiencing a significant sales slowdown due to cheaper copycat treatments from U.S. rival Eli Lilly & Co, with its stock plummeting approximately 48% in 2025 and an additional ~26% drop in 2026.
- Decline in Asset Management: Novo Holdings A/S reported a decrease in assets under management from DKK 1,060B (€142B) in 2024 to DKK 694B (€93B) last year, primarily reflecting a substantial decline in Novo Nordisk's market value.
- Shareholder Return Initiatives: The board proposed a final dividend of DKK 7.95 for 2025 and initiated a DKK 15B buyback program, aiming to bolster shareholder confidence and stabilize the stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 38.430
Low
42.00
Averages
54.67
High
70.00
Current: 38.430
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Expands Obesity Treatment Access in Japan
- Self-Funded Treatment Pathways: Novo Nordisk aims to broaden access to GLP-1 drug Wegovy by collaborating with physicians and patients on self-funded treatment options, addressing the issue that many individuals cannot access treatment for various reasons.
- Intensifying Market Competition: The company is experiencing a significant sales slowdown due to cheaper copycat treatments from U.S. rival Eli Lilly & Co, with its stock plummeting approximately 48% in 2025 and an additional ~26% drop in 2026.
- Decline in Asset Management: Novo Holdings A/S reported a decrease in assets under management from DKK 1,060B (€142B) in 2024 to DKK 694B (€93B) last year, primarily reflecting a substantial decline in Novo Nordisk's market value.
- Shareholder Return Initiatives: The board proposed a final dividend of DKK 7.95 for 2025 and initiated a DKK 15B buyback program, aiming to bolster shareholder confidence and stabilize the stock price.
See More
Stopping GLP-1 Drugs Significantly Increases Health Risks
- Increased Cardiovascular Risks: A study from Washington University School of Medicine reveals that stopping GLP-1 drugs significantly raises the risks of heart attack, stroke, and death in diabetes patients, with a 4% increase in risk after six months and a 22% increase after two years of discontinuation.
- Importance of Treatment Continuity: The research indicates that patients who remain on GLP-1s experience an 18% reduction in cardiovascular risk over three years, while stopping treatment quickly reverses these protective effects, underscoring the necessity for long-term therapy.
- High Discontinuation Rates: Discontinuation rates for GLP-1 drugs range from 36% to 81%, primarily due to access issues and side effects like nausea and vomiting, highlighting a persistent challenge within the healthcare system that remains unresolved.
- Future Treatment Directions: Drug manufacturers are working on next-generation obesity and diabetes treatments that aim to provide comparable efficacy with fewer side effects, addressing the discontinuation issue and improving treatment sustainability.
See More
TrumpRx Drug Pricing Claims Found Inaccurate
- Drug Price Comparison: An investigation by The New York Times and three German news organizations reveals that Trump's claim of TrumpRx offering the lowest drug prices globally is inaccurate, as US patients may pay hundreds to over a thousand dollars monthly, while German patients pay little or nothing.
- Limited Drug Availability: TrumpRx only negotiates discounts for about 40 drugs and does not include costly treatments like cancer therapies, indicating limitations in drug variety and pricing that could affect patient treatment options.
- International Price Discrepancies: For instance, a one-month supply of Wegovy through TrumpRx costs $349, whereas out-of-pocket costs in Japan, France, Germany, and the UK are $163, $196, $198, and $222 respectively, highlighting the higher drug costs faced by US patients.
- Impact of Government Negotiations: The German healthcare system's ability to negotiate lower drug prices reflects a lack of effective price control mechanisms in the US, potentially leading to increased patient burdens and impacting overall healthcare spending.
See More
Hims & Hers Launches Waitlist for Ozempic and Wegovy
- Partnership Announcement: Hims & Hers Health Inc. has partnered with Novo Nordisk AS to launch a pre-launch waitlist for Ozempic and Wegovy, indicating a strategic move into the prescription drug market that could enhance its competitive edge in health technology.
- Priority Access: Users who sign up for the waitlist will gain priority access to the official launch of Ozempic and Wegovy, which not only improves user experience but may also attract more customers to Hims & Hers' telehealth services, potentially driving revenue growth.
- Market Reaction: Despite Hims & Hers shares declining nearly 1% in pre-market trading on Wednesday, retail sentiment on Stocktwits trended bullish, suggesting that investor confidence in the company's future prospects remains strong, which could influence subsequent stock performance.
- User Engagement: By encouraging user participation through high message volumes on social media platforms during the waitlist launch, Hims & Hers not only enhances its market presence but may also foster customer loyalty and engagement.
See More
High-Quality Healthcare Stocks Under $50
- Pfizer's Outlook: Pfizer's stock trades around $27 with a P/E ratio of 9, significantly below the healthcare industry's average of 17.8; with a robust pipeline in oncology and chronic weight management, the company is poised for substantial clinical advancements over the next five years, likely improving financial performance and boosting sales.
- Novo Nordisk's Market Potential: Priced at approximately $39 with a P/E ratio of 10.4, Novo Nordisk stands to benefit from the rapidly expanding weight-loss market, positioning itself as a leader in anti-obesity products, which could yield significant returns for patient investors over the next five to ten years.
- Exelixis' Innovative Growth: Exelixis, trading at around $41, has carved a niche in oncology with its Cabometyx therapy, and is expected to report ongoing revenue and earnings growth while developing new drugs to address the patent cliff in 2030, showcasing strong market prospects.
- Attractiveness of Oncology Market: Exelixis's zanzalintinib has shown effectiveness in treating metastatic colorectal cancer, which is the second leading cause of cancer death globally; given this market's potential, the company is likely to enhance its competitiveness through new product transformations.
See More
Eli Lilly Leads U.S. Weight Loss Drug Market
- Market Share Leadership: Eli Lilly commands a 60% share of the U.S. weight loss drug market, driven by strong performance of its tirzepatide products (Mounjaro and Zepbound), solidifying its leadership in the rapidly growing weight loss sector.
- Competitive Landscape: Viking Therapeutics is advancing its VK2735 candidate through clinical trials, with strong results suggesting it could enter phase 3 trials in Q3, indicating potential competition against Lilly and Novo Nordisk's offerings, intensifying market rivalry.
- Demand and Supply Dynamics: The demand for weight loss drugs remains high, at times exceeding supply, providing Viking with an opportunity to carve out market share if its candidate successfully completes trials and gains regulatory approval.
- Investment Opportunity: Despite Eli Lilly's stock dropping about 8% this year, its forward P/E ratio has decreased to 28x, indicating a favorable investment opportunity in this weight loss leader, especially with the potential regulatory approval of its oral weight loss drug on the horizon.
See More
Novo Nordisk Expands Obesity Treatment Access in Japan
- Self-Funded Treatment Pathways: Novo Nordisk aims to broaden access to GLP-1 drug Wegovy by collaborating with physicians and patients on self-funded treatment options, addressing the issue that many individuals cannot access treatment for various reasons.
- Intensifying Market Competition: The company is experiencing a significant sales slowdown due to cheaper copycat treatments from U.S. rival Eli Lilly & Co, with its stock plummeting approximately 48% in 2025 and an additional ~26% drop in 2026.
- Decline in Asset Management: Novo Holdings A/S reported a decrease in assets under management from DKK 1,060B (€142B) in 2024 to DKK 694B (€93B) last year, primarily reflecting a substantial decline in Novo Nordisk's market value.
- Shareholder Return Initiatives: The board proposed a final dividend of DKK 7.95 for 2025 and initiated a DKK 15B buyback program, aiming to bolster shareholder confidence and stabilize the stock price.
See More
Stopping GLP-1 Drugs Significantly Increases Health Risks
- Increased Cardiovascular Risks: A study from Washington University School of Medicine reveals that stopping GLP-1 drugs significantly raises the risks of heart attack, stroke, and death in diabetes patients, with a 4% increase in risk after six months and a 22% increase after two years of discontinuation.
- Importance of Treatment Continuity: The research indicates that patients who remain on GLP-1s experience an 18% reduction in cardiovascular risk over three years, while stopping treatment quickly reverses these protective effects, underscoring the necessity for long-term therapy.
- High Discontinuation Rates: Discontinuation rates for GLP-1 drugs range from 36% to 81%, primarily due to access issues and side effects like nausea and vomiting, highlighting a persistent challenge within the healthcare system that remains unresolved.
- Future Treatment Directions: Drug manufacturers are working on next-generation obesity and diabetes treatments that aim to provide comparable efficacy with fewer side effects, addressing the discontinuation issue and improving treatment sustainability.
See More
TrumpRx Drug Pricing Claims Found Inaccurate
- Drug Price Comparison: An investigation by The New York Times and three German news organizations reveals that Trump's claim of TrumpRx offering the lowest drug prices globally is inaccurate, as US patients may pay hundreds to over a thousand dollars monthly, while German patients pay little or nothing.
- Limited Drug Availability: TrumpRx only negotiates discounts for about 40 drugs and does not include costly treatments like cancer therapies, indicating limitations in drug variety and pricing that could affect patient treatment options.
- International Price Discrepancies: For instance, a one-month supply of Wegovy through TrumpRx costs $349, whereas out-of-pocket costs in Japan, France, Germany, and the UK are $163, $196, $198, and $222 respectively, highlighting the higher drug costs faced by US patients.
- Impact of Government Negotiations: The German healthcare system's ability to negotiate lower drug prices reflects a lack of effective price control mechanisms in the US, potentially leading to increased patient burdens and impacting overall healthcare spending.
See More
Hims & Hers Launches Waitlist for Ozempic and Wegovy
- Partnership Announcement: Hims & Hers Health Inc. has partnered with Novo Nordisk AS to launch a pre-launch waitlist for Ozempic and Wegovy, indicating a strategic move into the prescription drug market that could enhance its competitive edge in health technology.
- Priority Access: Users who sign up for the waitlist will gain priority access to the official launch of Ozempic and Wegovy, which not only improves user experience but may also attract more customers to Hims & Hers' telehealth services, potentially driving revenue growth.
- Market Reaction: Despite Hims & Hers shares declining nearly 1% in pre-market trading on Wednesday, retail sentiment on Stocktwits trended bullish, suggesting that investor confidence in the company's future prospects remains strong, which could influence subsequent stock performance.
- User Engagement: By encouraging user participation through high message volumes on social media platforms during the waitlist launch, Hims & Hers not only enhances its market presence but may also foster customer loyalty and engagement.
See More
High-Quality Healthcare Stocks Under $50
- Pfizer's Outlook: Pfizer's stock trades around $27 with a P/E ratio of 9, significantly below the healthcare industry's average of 17.8; with a robust pipeline in oncology and chronic weight management, the company is poised for substantial clinical advancements over the next five years, likely improving financial performance and boosting sales.
- Novo Nordisk's Market Potential: Priced at approximately $39 with a P/E ratio of 10.4, Novo Nordisk stands to benefit from the rapidly expanding weight-loss market, positioning itself as a leader in anti-obesity products, which could yield significant returns for patient investors over the next five to ten years.
- Exelixis' Innovative Growth: Exelixis, trading at around $41, has carved a niche in oncology with its Cabometyx therapy, and is expected to report ongoing revenue and earnings growth while developing new drugs to address the patent cliff in 2030, showcasing strong market prospects.
- Attractiveness of Oncology Market: Exelixis's zanzalintinib has shown effectiveness in treating metastatic colorectal cancer, which is the second leading cause of cancer death globally; given this market's potential, the company is likely to enhance its competitiveness through new product transformations.
See More
Eli Lilly Leads U.S. Weight Loss Drug Market
- Market Share Leadership: Eli Lilly commands a 60% share of the U.S. weight loss drug market, driven by strong performance of its tirzepatide products (Mounjaro and Zepbound), solidifying its leadership in the rapidly growing weight loss sector.
- Competitive Landscape: Viking Therapeutics is advancing its VK2735 candidate through clinical trials, with strong results suggesting it could enter phase 3 trials in Q3, indicating potential competition against Lilly and Novo Nordisk's offerings, intensifying market rivalry.
- Demand and Supply Dynamics: The demand for weight loss drugs remains high, at times exceeding supply, providing Viking with an opportunity to carve out market share if its candidate successfully completes trials and gains regulatory approval.
- Investment Opportunity: Despite Eli Lilly's stock dropping about 8% this year, its forward P/E ratio has decreased to 28x, indicating a favorable investment opportunity in this weight loss leader, especially with the potential regulatory approval of its oral weight loss drug on the horizon.
See More
